It has been proposed that combined inhibition of tyrosine and serine/threonine kinases by drugs such as sorafenib (10 mg/kg/day) may offer an option to treat PAH and associated RV remodeling in different preclinical models [8, 10]. Here, MARK2 is linked to pulmonary arterial hypertension.